H.C. Wainwright lowered the firm’s price target on Annovis Bio (ANVS) to $10 from $12 and keeps a Buy rating on the shares. The firm says the company’s buntanetap Alzheimer’s disease pivotal trial remains in progress. It cites a lengthier time to potential approval for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio Reports Q2 2025 Progress and Financials
- Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know
- Annovis Bio’s Strategic Advancements and Phase 3 Study Progress Support Buy Rating
- Annovis Bio completes full patent transfer to crystal buntanetap
- Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors